lifestyle.newsblaze.com

Author: Immunic, Inc.

Immunic to Participate in Scientific and Medical Conferences in April

April 9, 2026
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

April 1, 2026
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

March 31, 2026
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

March 10, 2026
Immunic to Participate in Investor Conferences in March

March 3, 2026
Immunic Announces Closing of Oversubscribed Private Placement Financing

February 17, 2026
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

February 14, 2026
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

February 4, 2026
Immunic Highlights 2025 Accomplishments and Upcoming Milestones

January 7, 2026
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

November 27, 2025